Brain atrophy in multiple sclerosis: What we know and would like to know

Multiple Sclerosis

Volumn 12, Issue 6, 2006, Pages 679-687

  Simon, Jack H ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Atrophy; Brain; Clinical trials; Degeneration; MRI; Multiple sclerosis; Spinal cord

Indexed keywords

ALEMTUZUMAB; APOLIPOPROTEIN E4; BETA1A INTERFERON; CLADRIBINE; GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MYELIN BASIC PROTEIN; PLACEBO; PREDNISONE;

ASTROCYTOSIS; AXONAL INJURY; BRAIN ATROPHY; BRAIN SIZE; CLINICAL FEATURE; CLINICAL TRIAL; CORPUS CALLOSUM; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG PULSE THERAPY; GENETIC ASSOCIATION; GRAY MATTER; HISTOPATHOLOGY; HUMAN; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; NERVE FIBER DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PATHOPHYSIOLOGY; PHENOTYPE; PROGNOSIS; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SPINAL CORD ATROPHY; TREATMENT OUTCOME;

ATROPHY; BRAIN; HUMANS; MULTIPLE SCLEROSIS; SPINAL CORD;

EID: 33846330213     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458506070823     Document Type: Review

References (71)

1. Miller DH, Barkhof F, Frank JA, Parker GJM, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance [review]. Brain 2002; 125: 1676-95.
2. Fisher E, Rudick RA, Simon JH, Cutter G, Baier M, Lee J-C et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59: 1412-20.
3. Simon JH. Brain and spinal cord atrophy in multiple sclerosis: role as a surrogate measure of disease progression. CNS Drugs 2001; 15: 427-36.
4. Pelletier D, Garrison K, Henry R. Measurement of whole-brain atrophy in multiple sclerosis. J Neuroimag 2004; 14: 11S-9S.
5. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 1996; 6: 259-74.
6. Miller DH, Thompson AJ, Filippi M. Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J Neurol 2003; 250: 1407-19.
7. Perry VH, Anthony DC. Axon damage and repair in multiple sclerosis. Philos Trans R Soc Lond B Biol Sci 1999; 354:1641-47.
8. Bjartmar C, Trapp BD. Axonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotox Res 2003; 5: 157-64.
9. Ganter P, Prince C, Esiri MM. Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol Appl Neurobiol 1999; 25: 459-67.
10. Lovas G, Szilagyi N, Majtenyi K, Palkovits M, Komoly S. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 2000; 123: 308-17.
11. DeLuca GC, Ebers GC, Esiri MM. Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain 2004; 127: 1009-18.
12. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000; 48: 893-901.
13. Pelletier J, Suchet L, Witjas T, Habib M, Guttmann CR, Salamon G et al. A longitudinal study of callosal atrophy and interhemispheric dysfunction in relapsing-remitting multiple sclerosis. Arch Neurol 2001; 58:105-11.
14. Ranjeva JP, Pelletier J, Confort-Gouny S, Ibarrola D, Audoin B, Le FY et al. MRI/MRS of corpus callosum in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2003; 9: 554-65.
15. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-27.
16. Simon JH, Jacobs LD, Campion MK, Rudick RA, Cookfair DL, Herndon RM et al., and The Multiple Sclerosis Collaborative Research Group (MSCRG). A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology 1999; 53: 139-48.
17. Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 2000; 47: 391-95.
18. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain 2000; 123: 1845-49.
19. Simon JH, Jacobs L, Kinkel RP. Transcallosal bands: a sign of neuronal tract degeneration in early MS? Neurology 2001; 57: 1888-90.
20. Simon JH. Linear and regional measures of brain atrophy in multiple sclerosis. In Zivadinov R, Bakshi R eds. Brain and spinal cord atrophy in multiple sclerosis. Nova Science Publishers, Inc., 2004.
21. Hickman SJ, Toosy AT, Jones SJ, Altmann DR, Miszkiel KA, MacManus DG et al. Serial magnetization transfer imaging in acute optic neuritis. Brain 2004; 127: 692-700.
22. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain 2001; 124: 1813-20.
23. Coleman MP, Perry VH. Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci 2002; 25: 532-37.
24. Griffin JW, George R, Lobato C, Tyor WR, Yan LC, Glass JD. Macrophage responses and myelin clearance during Wallerian degeneration: relevance to immune-mediated demyelination. J Neuroimmunol 1992; 40: 153-65.
25. Thomalla G, Glauche V, Koch MA, Beaulieu C, Weiller C, Rother J. Diffusion tensor imaging detects early Wallerian degeneration of the pyramidal tract after ischemic stroke. Neuroimage 2004; 22: 1767-74.
26. Kuhn MJ, Mikulis DJ, Ayoub DM, Kosofsky BE, Davis KR, Taveras JM. Wallerian degeneration after cerebral infarction: evaluation with sequential MR imaging. Radiology 1989; 172: 179-82.
27. Buss A, Brook GA, Kakulas B, Martin D, Franzen R, Schoenen J et al. Gradual loss of myelin and formation of an astrocytic scar during Wallerian degeneration in the human spinal cord. Brain 2004; 127: 34-44.
28. Becerra JL, Puckett WR, Hiester ED, Quencer RM, Marcillo AE, Post MJ et al. MR-pathologic comparisons of Wallerian degeneration in spinal cord injury. AJNR Am J Neuroradiol 1995; 16: 125-33.
29. Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 2001; 57: 1248-52.
30. Prineas JW, Barnard RO, Kwon EE, Sharer LR, Cho ES. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 1993; 33: 137-51.
31. Raine CS, Wu E. Multiple sclerosis: remyelination in acute lesions. J Neuropathol Exp Neurol 1993; 52: 199-204.
32. Prineas JW, Connell F. Remyelination in multiple sclerosis. Ann Neurol 1979; 5: 22-31.
33. Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002; 52: 650-53.
34. Wylezinska M, Cifelli A, Jezzard P, Palace J, Alecci M, Matthews PM. Thalamic neurodegeneration in relapsing-remitting multiple sclerosis. Neurology 2003; 60: 1949-54.
35. Bakshi R, Benedict RH, Bermel RA, Caruthers SD, Pull SR, Tjoa CW et al. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol 2002; 59: 62-68.
36. De Stefano N, Matthews PM, Filippi M, Agosta F, De Luca M, Bartolozzi ML et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003; 60: 1157-62.
37. Quarantelli M, Ciarmiello A, Morra VB, Orefice G, Larobina M, Lanzillo R et al. Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load. Neuroimage 2003; 18: 360-66.
38. Dalton CM, Chard DT, Davies GR, Miszkiel KA, Altmann DR, Fernando K et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004; 127: 1101-107.
39. Chard DT, Griffin CM, Rashid W, Davies GR, Altmann DR, Kapoor R et al. Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis. Mult Scler 2004; 10: 387-91.
40. Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain 1999; 122: 17-26.
41. Bo L, Vedeler CA, Nyland HI, Trapp BD, Mork SJ. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003; 62: 723-32.
42. Sailer M, Fischl B, Salat D, Tempelmann C, Schonfeld MA, Busa E et al. Focal thinning of the cerebral cortex in multiple sclerosis. Brain 2003; 126: 1734-44.
43. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001; 50: 389-400.
44. Thompson A. Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis. Mult Scler 2004; 110: S2-S7.
45. Stevenson VL, Ingle GT, Miller DH, Thompson AJ. Magnetic resonance imaging predictors of disability in primary progressive multiple sclerosis: a 5-year study. Mult Scler 2004; 10: 398-401.
46. Filippi M, Bozzali M, Rovaris M. Gonen O, Kesavadas C, Ghezzi A et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003; 126: 433-37.
47. Lassmann H. Brain damage when multiple sclerosis is diagnosed clinically. Lancet 2003; 361: 1317-18.
48. Dalton CM, Brex PA, Jenkins R, Fox NC, Miszkiel KA, Crum WR et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 73: 141-47.
49. Kinkel P, Kollman C, Glassman A, Fisher E, Simon J, O'Connor P et al. The development of brain atrophy 5 years after a first clinical demyelinating event [abstract]. Neurology 2004; 62: A424.
50. The CHAMPS Study Group. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 2002; 59: 998-1005.
51. Enzinger C, Ropele S, Smith S, Strasser-Fuchs S, Poltrum B, Schmidt H et al. Accelerated evolution of brain atrophy and 'black holes' in MS patients with APOE-epsilon 4. Ann Neurol 2004; 55: 563-69.
52. Simon JH. From enhancing lesions to brain atrophy in relapsing MS. J Neuroimmunol 1999; 98: 7-15.
53. Rudick RA, Fisher E, Lee J-C, Simon JH, Jacobs LD, and the Multiple Sclerosis Collaborative Research Group. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 1999; 53: 1698-704.
54. Fisher E, Rudick RA, Cutter G, Baier M, Miller D, Weinstock-Guttman B et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 2000; 6: 373-77.
55. Paolillo A, Piattella MC, Pantano P, Di Legge S, Caramia F, Russo P et al. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA. J Neurol 2004; 251:432-39.
56. Chard DT, Griffin CM, Parker GJM, Kapoor R, Thompson AJ, Miller DH. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 2002; 125:327-37.
57. Leist TP, Gobbini MI, Frank JA, McFarland HF. Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis. Arch Neurol 2001; 58: 57-60.
58. Luks TL, Goodkin DE, Nelson SJ, Majumdar S, Bacchetti P, Portnoy D et al. A longitudinal study of ventricular volume in early relapsing-remitting multiple sclerosis. Mult Scler 2000; 6: 332-37.
59. Kalkers NF, Vrenken H, Uitdehaag BM, Polman CH, Barkhof F. Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue. Mult Scler 2002; 8: 410-14.
60. Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46: 296-304.
61. Jones CK, Riddehough A, Li DK, Zhao G, Paty DW, and the PRISIMS Study Group. MRI cerebral atrophy in relapsing-remitting MS: results from the PRISMS trial [abstract]. Neurology 2001; 56: 379.
62. Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 1489-96.
63. Frank JA, Richert N, Bash C, Stone L, Calabresi PA, Lewis B et al. Interferon β-1b slows progression of atrophy in RRMS: three-year follow-up in NAb - and NAb+ patients. Neurology 2004; 62: 719-25.
64. Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 2000; 123: 2256-63.
65. Rudick RA. Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis. J Neuroimag 2004; 14: 54S-64S.
66. Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain 2001; 124: 1803-12.
67. Rovaris M, Filippi M. Treatment effects on MRI measures of central nervous system atrophy in multiple sclerosis. In Zivadinov R, Bakshi R eds. Brain and spinal cord atrophy in multiple sclerosis, Chapter XI. Nova Biomedical Books, 2004:175-90.
68. Leary SM, Miller DR, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon β-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003; 60: 44-51.
69. Fillippi M, Rovaris M, Iannucci G, Mennen S, Sormani MP, Comi G. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 2000; 55: 1714-18.
70. Paolillo A, Coles AJ, Molyneux PD, Gawne-Cain M. MacManus D, Barker GJ et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 1999; 53: 751-57.
71. Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57: 1239-47.